Building for the Future
Our portfolio includes therapeutic and diagnostic products
in early and late-stage development.
InSite Vision is building a rich product pipeline of innovative ophthalmic products, utilizing novel agents and a powerful drug delivery platform.
Our lead product, AzaSite® (azithromycin ophthalmic solution) 1%, is an ocular anti-infective product that contains the drug azithromycin. AzaSite, has been approved by the U.S. Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis. AzaSite is formulated with InSite Vision’s proprietary DuraSite® technology platform. Another late-stage product candidate formulated with DuraSite is ISV-502 (AzaSite Plus), currently in Phase 3 clinical trials. ISV-502 is a topical combination antibiotic/corticosteroid product in development for infection and inflammation of the eyelid and conjunctiva (blepharitis), a condition with unmet medical need and lack of treatment options. We are also leveraging our DuraSite drug delivery vehicle for new products
The AzaSite family currently includes AzaSite®, AzaSite Plus™, and AzaSite Xtra™ —all of which have been formulated with the DuraSite® technology platform.
1, 2
*For ex-U.S. markets only
Sold/Licensed
1, 2
3
- The U.S. Food & Drug Administration (FDA) has approved InSite Vision’s New Drug Application (NDA) for AzaSite (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis.
- Inspire Pharmaceuticals (NASDAQ:ISPH) has the responsibility to commercialize AzaSite in the U.S. and Canada in accordance with a completed license agreement. Ongoing activities are focused on licensing AzaSite in markets outside of the U.S. and Canada.
- The U.S. Food & Drug Administration (FDA) approved Bausch & Lomb's Besivance (besifloxacin ophthalmic suspension) 0.6% for the treatment of bacterial conjunctivitis.